STL Index for: Ravi R. Patel

Small-vessel vasculitides (SVV) are a group of disorders that occur due to primarily systemic inflammation or as sequelae of an infection, malignancy, or other rheumatic disease.

Ichthyosis management requires a multimodal approach, including topical and oral agents in addition to lifestyle modifications.

Tildrakizumab is a promising therapeutic option for patients with moderate-to-severe chronic plaque psoriasis. The specificity of the drug in targeting the p19 subunit of IL-23 allows for the high efficacy and safety of long-term treatment as demonstrated in clinical trials.

Methotrexate has been an important agent in the management of dermatologic conditions for decades. Although first indicated for the treatment of psoriasis, MTX has been shown to be a successful treatment option for a wide array of skin diseases.

Shingrix®, a new recombinant subunit vaccine, has shown a great deal of promise in the prevention of HZ in adults over the age of 50. The combination of zoster viral glycoprotein E and the AS01B adjuvant system make it a safe, efficacious option for the elderly as well as immunosuppressed individuals.

This review examines the clinical trials of topical diacerein and its role in Epidermolysis Bullosa Simplex. Diacerein cream was recently US FDA-approved in May 2018 for treatment of patients with EBS.

Glycopyrronium tosylate (Qbrexza), a topical anticholinergic therapy, has been shown to be effective in the treatment of primary axillary hyperhidrosis.